KBI Biopharma Acquires Merck Operation In Boulder
KBI Biopharma, Inc. has signed an agreement with Merck & Co., Inc. (known as Merck in the United States and Canada) to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado, effective May 1, 2014. Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third party customers.
“KBI will now offer expanded microbial development and manufacturing services up to 1500L scale, as well as continuing to offer our current full range of process development, analytical and formulation development and mammalian manufacturing services up to 2000L,” stated Joe McMahon, KBI’s President and CEO.
KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.
To date, KBI has helped to advance more than 220 molecules in 55 unique health indications for over 170 clients around the world.
For more information, visit: www.kbibiopharma.com